Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484 on ClinicalTrials.gov · last registry update 2017-03-03

Withdrawn before anyone was enrolled. Its estimated completion date, June 2018, has passed with no update to the record. Primary outcome, as filed: Change in HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Weill Medical College of Cornell University
Sponsor type: Other
Enrollment: 0
Started: 2016-06
Primary completion: 2018-06 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.